etigilimab,nivolumab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['#activate', 'biomarker', 'nivo', 'nivolumab', 'etigilimab', '$mreo', 'marker ', 'mereo']
#mereobiopharma reports clinical update and interim #biomarker analysis presented at #esmo22 from #activate phase 1b/2 open label study of #etigilimab (#antitigit #antibody #mph313) plus #nivolumab (#antipd1 #antibody) in #solidtumors #esmo22 $mreo 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.